← All Posts
IRW
Ironwood Pharmaceuticals, Inc.
June 17, 2026
•
Author: Phil Ratcliff
•
IRWD
| Item |
Proposal |
Vote |
| 1 |
Election of Directors: To elect eight director nominees numbered 01 through 08 to serve for a one-year term extending until the 2027 annual meeting of stockholders and their successors are duly elected and qualified. |
|
| 1.01 |
Mark Currie, Ph.D. |
✓ For(31.845)
|
| 1.02 |
Alexander Denner, Ph.D. |
✓ For(31.845)
|
| 1.03 |
Jon Duane |
✓ For(31.845)
|
| 1.04 |
Marla Kessler |
✓ For(31.845)
|
| 1.05 |
Thomas McCourt |
Withhold(31.845)
|
| 1.06 |
Julie McHugh |
✓ For(31.845)
|
| 1.07 |
Catherine Moukheibir |
✓ For(31.845)
|
| 1.08 |
Jay Shepard |
✓ For(31.845)
|
| 2 |
Approval, by non-binding advisory vote, of the compensation paid to the named executive officers. |
✗ Against(31.845)
|
| 3 |
Approval of an amendment to Ironwood Pharmaceuticals, Inc. Amended and Restated 2019 Equity Incentive Plan to increase the number of shares available for issuance thereunder by 10,000,000 shares. |
✓ For(31.845)
|
| 4 |
Ratification of the selection of KPMG LLP as Ironwood Pharmaceuticals, Inc.'s independent registered public accounting firm for 2026. |
✓ For(31.845)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial